CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Treasury	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2019			670,378,701
Beginning balance, shares (in shares) at Dec. 31, 2019				(549,907)
Beginning balance at Dec. 31, 2019	$ 1,614,759	$ (1,342)	$ 6,704	$ (1,791)	$ 3,142,993		$ (22,070)	$ (1,511,077)	$ (1,342)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	8,947				8,947
Exercise of common stock options and warrants (in shares)			206,875
Exercise of common stock options and warrants	756		$ 2		754
Net income (loss)	30,586							30,586
Other comprehensive income (loss)	17,845						17,845
Ending balance, shares (in shares) at Dec. 31, 2020			670,585,576
Ending balance, shares (in shares) at Dec. 31, 2020				(549,907)
Ending balance at Dec. 31, 2020	1,671,551		$ 6,706	$ (1,791)	3,152,694		(4,225)	(1,481,833)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	13,632				13,632
Exercise of common stock options and warrants (in shares)			445,437
Exercise of common stock options and warrants	1,081		$ 5		1,076
Conversion of 2025 convertible notes (in shares)			19,051,270	8,105,175
Conversion of 2025 convertible notes	55,275		$ 190		55,085
Net income (loss)	(30,143)							(30,143)
Other comprehensive income (loss)	$ (26,270)						(26,270)
Ending balance, shares (in shares) at Dec. 31, 2021			690,082,283
Ending balance, shares (in shares) at Dec. 31, 2021	(8,655,082)			(8,655,082)
Ending balance at Dec. 31, 2021	$ 1,685,126	$ (21,642)	$ 6,901	$ (1,791)	3,222,487	$ (39,100)	(30,495)	(1,511,976)	$ 17,458
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06
Equity-based compensation expense	$ 18,509				18,509
Exercise of common stock options and warrants (in shares)	211,187		629,837
Exercise of common stock options and warrants	$ (774)		$ 6		(780)
ModeX Acquisition (in shares)			90,594,044
ModeX Acquisition	221,662		$ 906		220,756
Net income (loss)	(328,405)							(328,405)
Other comprehensive income (loss)	$ (12,828)						(12,828)
Ending balance, shares (in shares) at Dec. 31, 2022			781,306,164
Ending balance, shares (in shares) at Dec. 31, 2022	(8,655,082)			(8,655,082)
Ending balance at Dec. 31, 2022	$ 1,561,648		$ 7,813	$ (1,791)	$ 3,421,872		$ (43,323)	$ (1,822,923)